- Record: found
- Abstract: found
- Article: not found
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon
1 ,
Wolfgang Eiermann ,
Nicholas Robert ,
Tadeusz Pienkowski ,
Miguel Martin ,
Michael Press ,
John Mackey ,
John Glaspy ,
Arlene Chan ,
Marek Pawlicki ,
Tamas Pinter ,
Vicente Valero ,
Mei-Ching Liu ,
Guido Sauter ,
Gunter von Minckwitz ,
Frances Visco ,
Valerie Bee ,
Marc Buyse ,
Belguendouz Bendahmane ,
Isabelle Tabah-Fisch ,
Mary-Ann Lindsay ,
Alessandro Riva ,
John Crown
Oct 06 2011
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab.
Related collections
Author and article information
Comments
Comment on this article
scite_
Similar content666
Cited by798
- Breast Cancer TreatmentAuthors: Adrienne Waks, Eric Winer
- Breast cancerAuthors: Michael Gnant, Nadia Harbeck